BioCryst Pharmaceuticals Inc (NAS:BCRX)
$ 7.78 0.11 (1.43%) Market Cap: 1.61 Bil Enterprise Value: 2.09 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 78/100

Q4 2018 BioCryst Pharmaceuticals Inc Earnings Call Transcript

Mar 04, 2019 / 01:30PM GMT
Operator

Good morning, ladies and gentlemen, and welcome to the BioCryst Fourth Quarter 2018 Earnings Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded for replay purposes.

It is now my pleasure to hand the conference over to John Bluth. Sir, you may begin.

John Bluth

Thanks, Brian. Good morning, and welcome to BioCryst's Fourth Quarter and Full Year 2018 Corporate Update and Financial Results Conference Call. Today's press release and accompanying slides are available on our website.

Participating on the call with me today are: CEO, Jon Stonehouse; CFO, Tom Staab; Chief Medical Officer, Dr. Bill Sheridan; and Chief Commercial Officer, Lynne Powell. Following their remarks, we will answer your questions.

Before we begin, I want to direct your attention to Slide 2, which discusses our use of forward-looking statements and potential risk factors regarding an investment in BioCryst. As detailed on the slide, today's conference call will contain forward-looking statements, including those statements

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot